Unknown

Dataset Information

0

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.


ABSTRACT: Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy, refractory disease, or histologic transformation (tFL) have limited progression-free and overall survival. We report efficacy and long-term follow-up of 21 patients with relapsed/refractory (R/R) FL (n = 8) and tFL (n = 13) treated on a phase 1/2 clinical trial with cyclophosphamide and fludarabine lymphodepletion followed by infusion of 2 × 106 CD19-directed chimeric antigen receptor-modified T (CAR-T) cells per kilogram. The complete remission (CR) rates by the Lugano criteria were 88% and 46% for patients with FL and tFL, respectively. All patients with FL who achieved CR remained in remission at a median follow-up of 24 months. The median duration of response for patients with tFL was 10.2 months at a median follow-up of 38 months. Cytokine release syndrome occurred in 50% and 39%, and neurotoxicity in 50% and 23% of patients with FL and tFL, respectively, with no severe adverse events (grade ≥3). No significant differences in CAR-T cell in vivo expansion/persistence were observed between FL and tFL patients. CD19 CAR-T cell immunotherapy is highly effective in adults with clinically aggressive R/R FL with or without transformation, with durable remission in a high proportion of FL patients. This trial was registered at clinicaltrials.gov as #NCT01865617.

SUBMITTER: Hirayama AV 

PROVIDER: S-EPMC6695558 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5774642 | biostudies-literature
| S-EPMC8282870 | biostudies-literature
| S-EPMC6486329 | biostudies-literature
| S-EPMC6245999 | biostudies-literature
| S-EPMC8557255 | biostudies-literature
| S-EPMC6880890 | biostudies-literature
| S-EPMC6620363 | biostudies-literature
| S-EPMC8189155 | biostudies-literature
| S-EPMC6954177 | biostudies-literature
| S-EPMC4039868 | biostudies-literature